Machine learning algorithms for predicting protein biomarkers in Alzheimer's disease: A systematic review and empirical comparison

Fangyu LI, Ying LI, Yan LI, Lingzhi XU, Bingqiu LI, Jianping JIA

Chinese Journal of Alzheimer's Disease and Related Disorders ›› 2026, Vol. 9 ›› Issue (5) : 291-297.

PDF(971 KB)
Home Journals Chinese Journal of Alzheimer's Disease and Related Disorders
Chinese Journal of Alzheimer's Disease and Related Disorders

Abbreviation (ISO4): Chinese Journal of Alzheimer's Disease and Related Disorders      Editor in chief: Jun WANG

About  /  Aim & scope  /  Editorial board  /  Indexed  /  Contact  / 
PDF(971 KB)
Chinese Journal of Alzheimer's Disease and Related Disorders ›› 2026, Vol. 9 ›› Issue (5) : 291-297. DOI: 10.3969/j.issn.2096-5516.2026.05.001
Commentary

Machine learning algorithms for predicting protein biomarkers in Alzheimer's disease: A systematic review and empirical comparison

Author information +
History +

Abstract

Objective: To explore the applicability and efficacy of different machine learning algorithms in predicting protein biomarkers for Alzheimer's disease (AD), thereby overcoming the analytical bottlenecks of high-dimensional proteomics data and facilitating early and accurate diagnosis of AD. Methods: This paper systematically reviews the basic principles of seven common machine learning algorithms—Random Forest, Lasso Regression, Support Vector Machine, XGBoost, Decision Tree, Neural Network and Logistic Regression—and their specific applications in the prediction of AD protein biomarkers. In addition, based on the cerebrospinal fluid proteomic data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI), we systematically compared the predictive performance of these seven algorithms across different feature dimensions through multiple cross-validation. Results: The results showed that Lasso Regression exhibited the best performance in the high-dimensional feature space (with a peak area under the curve of 0.970), making it suitable for biomarker screening across the entire proteome; Support Vector Machine demonstrated the optimal stability (with the area under the curve stably ranging from 0.920 to 0.950); Neural Network performed excellently in high-dimensional data and could capture complex nonlinear relationships; XGBoost showed the fastest growth in low-dimensional features; Random Forest and Decision Tree could generate interpretable outputs; and Logistic Regression was only applicable to low-dimensional scenarios. Finally, the advantages, disadvantages and applicability of the seven methods are summarized, and current challenges and future directions are discussed. Conclusions: Lasso regression, support vector machine, and neural networks have significant advantages in screening capability, stability, and nonlinear modeling, respectively. In practice, the most appropriate algorithm should be selected based on data dimensionality and specific needs to improve the accuracy of early AD diagnosis and its potential for clinical translation.

Key words

Alzheimer's disease / Machine learning / Protein biomarkers / Lasso regression / ADNI

Cite this article

Download Citations
Fangyu LI , Ying LI , Yan LI , et al . Machine learning algorithms for predicting protein biomarkers in Alzheimer's disease: A systematic review and empirical comparison[J]. Chinese Journal of Alzheimer's Disease and Related Disorders. 2026, 9(5): 291-297 https://doi.org/10.3969/j.issn.2096-5516.2026.05.001

References

[1]
Jia L, Du Y, Chu L, et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: A cross-sectional study[J]. Lancet Public Health, 2020, 5(12): e661-e671.
[2]
Ren F, Wei J, Chen Q, et al. Artificial intelligence-driven multi-omics approaches in Alzheimer's disease: Progress, challenges, and future directions[J]. Acta Pharm Sin B, 2025, 15(9): 4327-4385.
[3]
Strelnikova P A, Kononikhin A S, Zakharova N V, et al. Plasma protein panel for assessing the risk of Alzheimer's disease by MRM-MS analysis: The Study of two independent clinical cohorts[J]. Int J Mol Sci, 2025, 27(1):15.
[4]
Gao H, Zhan Y, Liu Y, et al. Systematic evaluation of blood contamination in nanoparticle-based plasma proteomics[J]. EMBO Mol Med, 2026, 18(1): 275-296.
[5]
Xu J, Doig A J, Michopoulou S, et al. Accurate and robust prediction of Amyloid-beta brain deposition from plasma biomarkers and clinical information using machine learning[J]. Front Aging Neurosci, 2025, 17: 1559459.
[6]
Erwan Scornet G H. Theory of random forests: A review[J]. HAL Open Science, 2025, 2025-03-26: 11-27.
[7]
郑金萍, 刘赵发, 胡珍珍, 等. 基于 mBagging 的随机森林[J]. 赣南师范大学学报, 2022, 43(3): 113-115.
[8]
张雨曦, 孙炜, 朱国栋, 等. 基于语音分析的机器学习模型识别阿尔茨海默病[J]. 中国医学物理学杂志, 2025, 42(5): 685-692.
[9]
Amin E, Elgammal Y M, Zahran M A, et al. Alzheimer's disease: New insight in assessing of amyloid plaques morphologies using multifractal geometry based on Naive Bayes optimized by random forest algorithm[J]. Sci Rep, 2023, 13(1): 18568.
[10]
Tao Q Q, Cai X, Xue Y Y, et al. Alzheimer's disease early diagnostic and staging biomarkers revealed by large-scale cerebrospinal fluid and serum proteomic profiling[J]. Innovation (Camb), 2024, 5(1): 100544.
[11]
Ali H, Shahzad M, Sarfraz S, et al. Application and impact of Lasso regression in gastroenterology: A systematic review[J]. Indian J Gastroenterol, 2023, 42(6): 780-790.
[12]
He S, Dou L, Li X, et al. Review of bioinformatics in Alzheimer's disease research[J]. Comput Biol Med, 2022, 143(13): 105269.
[13]
Yang S, Ye Z, He P, et al. Plasma proteomics for risk prediction of Alzheimer's disease in the general population[J]. Aging Cell, 2024, 23(12): e14330.
[14]
韩红娟, 秦瑶, 乔果果, 等. 基于Lasso Cox回归模型的早期阿尔茨海默病转归预测研究[J]. 中华疾病控制杂志, 2023, 27(8): 907-15.
[15]
Li Y, Chen Z, Wang Q, et al. Identification of hub proteins in cerebrospinal fluid as potential biomarkers of Alzheimer's disease by integrated bioinformatics[J]. J Neurol, 2023, 270(3): 1487-1500.
[16]
Meng F, Zhang X. Unveiling potential biomarkers in cerebrospinal fluid for amyloid pathological positivity in Non-Demented individuals[J]. J Prev Alzheimers Dis, 2024, 11(6): 1759-1766.
[17]
Pruneski JA, Pareek A. Support vector machines: Techniques and applications[J]. Hand clinics, 2026, 42(1): 19-25.
[18]
Laske C, Leyhe T, Stransky E, et al. Identification of a blood-based biomarker panel for classification of Alzheimer's disease[J]. Int J Neuropsychopharmacol, 2011, 14(9): 1147-1155.
[19]
Zhang F, Petersen M, Johnson L, et al. Recursive support vector machine biomarker selection for Alzheimer's disease[J]. J Alzheimers Dis, 2021, 79(4): 1691-1700.
[20]
Kim B H, Seo S W, Kim J, et al. Cerebrospinal fluid proteins in relation to longitudinal cognitive trajectories[J]. Alzheimers Dement, 2025, 21(11): e70894.
[21]
Xie Y, Tummala S P. Machine learning for sensor analytics: A comprehensive review and benchmark of boosting algorithms in healthcare, environmental, and energy applications[J]. Sensors (Basel), 2025, 25(23):7294.
[22]
Dubois K N, Pal S, Maher A C, et al. Dementia etiology classification using NULISA plasma biomarkers and machine learning[J]. Alzheimer's Dement, 2026, 22(6): e71603.
[23]
Wang J T, Zhi N, Xu G, et al. Speech digital biomarker combined with fluid biomarkers predict cognitive impairment through machine learning[J]. Alzheimers Res Ther, 2025, 17(1): 229.
[24]
Cumplido-mayoral I, Sanchez-benavides G, Vilor-tejedor N, et al. Neuroimaging-derived biological brain age and its associations with glial reactivity and synaptic dysfunction cerebrospinal fluid biomarkers[J]. Mol Psychiatry, 2025, 30(8): 3718-3728.
[25]
Jiang S, Qi P, Tian J, et al. MALT1 in cerebrospinal fluid: A prognostic biomarker and potential therapeutic target in Alzheimer's disease[J]. Front Neurol, 2025, 16: 1732729.
[26]
Blockeel H, Devos L, Frenay B, et al. Decision trees: From efficient prediction to responsible AI[J]. Front Artif Intell, 2023, 6: 1124553.
[27]
Chang H I, Ma M C, Huang K L, et al. Optimizing timing and cost-effective use of plasma biomarkers in Alzheimer's disease[J]. Alzheimers Res Ther, 2025, 17(1): 194.
[28]
Babapour Mofrad R, Schoonenboom N S M, Tijms BM, et al. Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease[J]. Alzheimers Dement (Amst), 2019, 11: 1-9.
[29]
Bombois S, Duhamel A, Salleron J, et al. A new decision tree combining Abeta 1-42 and p-Tau levels in Alzheimer’s diagnosis[J]. Current Alzheimer Research, 2013, 10(4): 357-364.
[30]
Choi R Y, Coyner A S, Kalpathy-cramer J, et al. Introduction to machine learning, neural networks, and deep learning[J]. Transl Vis Sci Technol, 2020, 9(2): 14.
[31]
Qin H, Shi X, Zhu Y, et al. Alzheimer's disease early screening and staged detection with plasma proteome using machine learning and convolutional neural network[J]. Eur J Neurosci, 2024, 60(2): 4034-4048.
[32]
An L, Pichet-binette A, Hristovska I, et al. Benchmarking the AI-based diagnostic potential of plasma proteomics for neurodegenerative disease in 17,170 people[J]. medRxiv, 2025, 21: e099373.
[33]
Park C, Joo G, Roh M, et al. Predicting the progression of mild cognitive impairment to Alzheimer's dementia using recurrent neural networks with a series of neuropsychological tests[J]. J Clin Neurol, 2024, 20(5): 478-486.
[34]
Park S, Kim D, Choi J H, et al. NeuroFANN: Identification of neuropathological subtypes in dementia with plasma proteins by using functionally annotated neural network[J]. Brief Bioinform, 2025, 26(4):bbaf366.
[35]
B L Y. Enhanced logistic regression using stacking algorithm for imbalanced and high-dimensional data[C]//Proceedings of the 4th international conference on machine learning, big data and artificial intelligence (MMBDAI 2024)[J]. Highlights in Science, Engineering and Technology, 2025, 136: 3-8.
[36]
Tsai W Y, Giesbertz P, Breimann S, et al. Multi-platform integration of brain and CSF proteomes reveals biomarker panels for Alzheimer's disease[J]. Brief Bioinform, 2026, 27(1):bbag012.
[37]
Wang X, Tang Y, Zhang Q, et al. An integrated CSF-serum biomarker model for predicting clinical progression in Alzheimer's disease[J]. Front Aging Neurosci, 2026, 18: 1728675.
[38]
Schraen-maschke S, Duhamel A, Vidal J S, et al. The free plasma amyloid Abeta(1)(-)(42)/Abeta(1)(-)(40) ratio predicts conversion to dementia for subjects with mild cognitive impairment with performance equivalent to that of the total plasma Abeta(1)(-)(42)/Abeta(1)(-)(40) ratio. The BALTAZAR study[J]. Neurobiol Dis, 2024, 193: 106459.
[39]
Dong j M, Zhong H. Systematic review: Proteomics-driven multi-omics integration for Alzheimer's disease pathology and precision medicine[J]. Neurol Int, 2025, 17(12):197.
[40]
Modali V A, Pavanya M, Arjunan R V, et al. AlzStack: Forecasting early-onset Alzheimer's with an explainable AI system using multiple data balancing techniques[J]. Glob Epidemiol, 2026, 11: 100235.

Footnotes

利益冲突声明 所有作者在本研究中不存在任何利益冲突。

PDF(971 KB)

Accesses

Citation

Detail

Sections
Recommended

/

〈 〉